BioSphere’s UFE Awareness Campaign Continues with NBC-TV "Today” Show Appearance by Beverly Johnson

BioSphere Medical, Inc. (NASDAQ: BSMD) ("BioSphere”), a medical device company that has pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a minimally invasive, image-guided medical procedure called embolotherapy, today announced that supermodel, entrepreneur, and actress Beverly Johnson appeared on NBC-TV’s "Today” show this morning with Erika Banks M.D., Ob/Gyn from the Montefiore Fibroid Center in the Bronx, New York, and Paula Grant, a patient who underwent uterine fibroid embolization (UFE). The appearance on the nation’s top-rated morning show is part of a targeted campaign called "Ask4Tell4” aimed at raising awareness of treatment options, including UFE, for symptomatic uterine fibroids.

Richard Faleschini, BioSphere Medical’s president and chief executive officer, said, "We are pleased with Beverly’s appearance on "Today” in front of such a large national audience, which was done in conjunction with our ongoing Ask4Tell4 campaign. This is an important campaign for us and a needed educational tool for women because, unfortunately, millions are suffering from fibroids in silence, or have not yet been fully informed of their treatment options. Beverly is a compelling patient advocate who has participated in a number of radio interviews and television news programs since our awareness campaign was launched in September. We are also pleased that several articles have also been published with respect to our Ask4Tell4 message.”

In the segment, cohosted by Kathie Lee Gifford and Hoda Kotb, Ms. Johnson reminded viewers that uterine fibroids are very prevalent in women generally, and particularly in African-American women, and recommended that all women research the treatment options for fibroids and ensure that they are fully informed by their physicians about fibroids and the procedures available to treat them. She also said women can help one another by telling other women about the treatment options available, including UFE. Paula Grant discussed her experience, the treatment options that she chose – first myomectomy which wasn’t successful, then UFE which was successful – and her recovery. Dr. Banks provided details on the UFE procedure and emphasized that it is one of several nonsurgical treatment options now available to women.

Ms. Johnson, who underwent a hysterectomy in 1999 to address uterine fibroids, became a spokesperson for the National Women’s Health Resource Center as part of a campaign to educate women about alternatives to hysterectomy. Her story, treatment options for uterine fibroids, and questions that women should ask their doctors are available at www.ask4tell4.com. To access the "Today” show segment, click on http://today.msnbc.msn.com/id/26184891/vp/18424824#27786305.

According to Nielsen ratings, the fourth hour of The Today Show drew 1.7 million viewers during the week of October 12, 2008.

About BioSphere Medical, Inc.

BioSphere Medical, Inc., a medical device company based in Rockland, Massachusetts, seeks to develop and commercialize products used in minimally invasive diagnostic and therapeutic applications based upon its pioneering proprietary bioengineered microsphere technology. The Company's core technologies, patented bioengineered polymers and manufacturing methods, are used to produce microscopic spherical materials with unique beneficial properties that are designed for a variety of medical applications. BioSphere's principal focus is the treatment of symptomatic uterine fibroids using a procedure called uterine fibroid embolization, or UFE. The Company's products continue to gain acceptance in this rapidly emerging procedure, as well as in a number of other new and established medical treatments.

Cautionary Note About Web Site References

BioSphere cautions you that this press release contains a link to a Web site that is not operated, reviewed or controlled by BioSphere. BioSphere assumes no responsibility for the information or statements found on this or other Web sites, and such information and statements are not incorporated by reference into this press release. Moreover, BioSphere also includes in this press release a link to its own Web site. BioSphere cautions you that the information on its Web site is not incorporated by reference into this press release and should not be considered to be a part of this press release.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the expected favorable benefits of the Company’s Ask4Tell4 marketing campaign and of UFE as a treatment option of choice for symptomatic fibroids. The Company may use words such as "plans," "seeks," "projects," "believes," "may," "anticipates," "estimates," "should," "intends," "looking forward," and similar expressions to identify these forward-looking statements. There are a number of important factors that may affect the Company's actual performance and results and the accuracy of its forward-looking statements, many of which are beyond the Company's control and are difficult to predict. These important factors include, without limitation, risks relating to: the failure of the Company to successfully execute on its sales and marketing strategies, including its Ask4Tell4 campaign; the failure of the Company to successfully develop, commercialize and achieve widespread market acceptance of its products; the failure of the Company to increase the rate of UFE procedures, and concomitant use of its products for UFE, with its expanded sales force and its recently initiated sales and marketing strategies; the failure of the Company to achieve or maintain necessary regulatory approvals; the Company's ability to obtain and maintain patent and other proprietary protection; the absence of, or delays or cancellations of, product orders, and delays, difficulties or unanticipated costs in the introduction of new products; competitive pressures and the risk of product liability claims, either of which may impact market acceptance of products and adversely affect the Company's operating results; the inability of the Company to successfully execute on its plans and strategies for future growth; the inability of the Company to raise additional funds in the near term to finance the development, marketing, and sales of its products; general economic and market conditions, both domestically and abroad; and, risk factors described in the section titled "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, as filed by the Company with the Securities and Exchange Commission, and described in other filings made by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company anticipates that subsequent events and developments may cause its forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances after the date of this press release.